Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Merck Allocates 3 Million Courses of Molnupiravir to be Provided in First Half of 2022 for Use in Low- and Middle-Income Countries KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the signing of a long-term supply…